September 8, 2026Stocks·Bullish·pharma
AstraZeneca's tozorakimab shows significant reduction in COPD exacerbations in Phase III trials
AstraZeneca announced that its drug tozorakimab showed a statistically significant reduction in COPD exacerbations across broad patient populations in the OBERON and TITANIA Phase III trials, a medicine the company expects to generate multibillion-dollar sales.
Detected & updated continuously · Source: Nebula
Story subjects
Sources
@WSJ
AstraZeneca said its new drug for COPD showed benefits across a broad patient population in late-stage clinical trials, boosting a medicine the company expects to generate multibillion-dollar sales. https://t.co/x5gE5curk3
@blckchaindaily
🚨 ASTRAZENECA $AZN TOZORAKIMAB SHOWS STATISTICALLY SIGNIFICANT REDUCTION IN COPD EXACERBATIONS IN OBERON, TITANIA PHASE III TRIALS